In:
Clinical and Applied Thrombosis/Hemostasis, SAGE Publications, Vol. 18, No. 2 ( 2012-04), p. 181-184
Kurzfassung:
The aim of our study was to assess hospital budget implications of substituting dabigatran for warfarin in patients enrolled in a large anticoagulation service. The study population was identified using criteria from randomized controlled trials of dabigatran. We obtained labor costs ($483 per patient) from the hospital’s anticoagulation service budget, laboratory costs of international normalized ratio (INR) tests ($267 per patient), and wholesale costs of warfarin 5 mg tablets ($31 per patient) and dabigatran 150 mg capsules ($2464 per patient). A total of 1774 (93.5%) of 1898 patients were eligible to substitute dabigatran for warfarin. The annual projected hospital expense for anticoagulation with dabigatran was $4 371 136, attributable to drug cost alone. The annual projected cost of warfarin management was $1 385 494. This was comprised of $856 842 for labor, $473 658 for INR testing, and $54 994 for the drug cost of warfarin. Substitution will result in increased expense due to drug cost.
Materialart:
Online-Ressource
ISSN:
1076-0296
,
1938-2723
DOI:
10.1177/1076029611416642
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2012
ZDB Id:
2230591-9
